BioStock: BioInvent reports clinical progress with BI-1206

A fourth complete response has been observed in the phase I/II trial of BioInvent´s lead drug candidate BI-1206 in combination with rituximab in non-Hodgkin’s lymphoma. According to the company´s CEO Martin Welschof, this is very encouraging news for NHL patients who are in urgent need of improved treatment options.

Read the article at biostock.se:

https://www.biostock.se/en/2023/04/bioinvent-reports-clinical-progress-with-bi-1206/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/